Uploaded February 2025 | Updated September 2026, 2 weeks ago
Mutations in the HIPPO pathway drive activation of the TEAD family of transcription factors, which in turn promotes the expression of genes involved in cell proliferation and survival, in addition to resistance to targeted therapies. Subsequently, TEAD pathway over-activation is associated with tumorigenesis, making this family of proteins an attractive target for oncology drug development. Here, our Chief Medical Officer Sujata Rao and Associate Director (BD) Sean Cullen explore the latest developments in the TEAD inhibitor space and highlight Insilico Medicine's internal TEAD inhibitor program which has just entered phase 1 clinical trials.
Mutations in the HIPPO pathway drive activation of the TEAD family of transcription factors, which in turn promotes the expression of genes involved in cell proliferation and survival, in addition to resistance to targeted therapies. Subsequently, TEAD pathway over-activation is associated with tumorigenesis, making this family of proteins an attractive target for oncology drug development. Here, our Chief Medical Officer Sujata Rao and Associate Director (BD) Sean Cullen explore the latest developments in the TEAD inhibitor space and highlight Insilico Medicine's internal TEAD inhibitor program which has just entered phase 1 clinical trials.
